Shattuck Labs (NasdaqGS:STTK) FY Conference Transcript

Summary of Shattuck Labs FY Conference Call Company Overview - Company: Shattuck Labs (NasdaqGS:STTK) - Focus: Development of DR3 blocking antibodies, specifically targeting the TL1A pathway in inflammatory bowel disease (IBD) [1][2] Core Points and Arguments - Mechanism of Action: - DR3 is the receptor for TL1A, and blocking this receptor may provide superior efficacy compared to TL1A blocking antibodies due to its stability and lower immunogenicity [2][4] - TL1A blocking antibodies have a high incidence of anti-drug antibodies (ADA), with over 64% of patients developing ADA, which can lead to reduced efficacy [5][11] - Clinical Development: - Shattuck Labs is currently in Phase I clinical trials for their human DR3 blocking antibody, SL-325, and expects to share data in Q2 [6][10] - A Phase 2b randomized controlled study in Crohn's disease is planned to start in Q3, with a target enrollment of 170-180 patients [26][28] - Efficacy Expectations: - The company aims for a 100% blockade of TL1A signaling, which is expected to lead to improved clinical outcomes compared to existing therapies [13][18] - Previous studies indicate that ADA levels significantly impact the efficacy of TL1A antibodies, with a 50% drop in efficacy observed as ADA titers increase [18][19] - Safety Profile: - The engineered SL-325 antibody is designed to minimize off-target effects and does not cause receptor-mediated endocytosis of DR3, reducing the risk of adverse events [8][9][10] - Non-human primate studies showed no evidence of T cell proliferation or adverse effects, supporting the safety profile expected in humans [25] Additional Important Content - Competitive Landscape: - The competitive landscape includes various companies developing TL1A blocking antibodies, while Shattuck Labs is one of the few focusing on DR3 blocking antibodies [6] - Future Directions: - Plans to develop bispecific antibodies targeting DR3 are underway, with expectations to share details later this year [34] - The company is considering the potential for life cycle management and indication splitting for SL-425, a half-life extended version of SL-325 [32] - Market Considerations: - The company believes that demonstrating efficacy in Crohn's disease will also translate to ulcerative colitis, given the mechanistic similarities and current market dynamics [27] - Regulatory and Development Strategy: - The Phase 2b study will assess both high and low doses against a placebo, with a focus on achieving a minimum of 25% improvement in endoscopic response rates [28][29] This summary encapsulates the key points discussed during the conference call, highlighting Shattuck Labs' strategic focus on DR3 blocking antibodies and their anticipated impact on the treatment of inflammatory bowel disease.